The custom
antibody market is set to witness a CAGR of ~10% during the
forecast period. The market growth is primarily driven by
expanding R&D activities, increasing demand for customized antibodies,
growing adoption of targeted therapeutics, and advancements in antibody
engineering and production technologies. However, the high costs associated
with development and the time-intensive nature of antibody generation present
challenges that may slow market adoption.
Custom antibodies are indispensable tools used
by researchers and clinicians in life science research, medicine and
diagnostics. These antibodies are designed in laboratories to identify and
target a specific antigen of interest with high accuracy and precision that may
not be addressed by commercially available antibodies. Antigen synthesis, serum
collection, animal immunization (usually in rabbits, mice, or goats), and
purification are some of the procedures which are used to produce custom
antibodies.
Download a free sample report now 👉
https://meditechinsights.com/custom-antibody-market/request-sample/
Targeted therapeutics drive growth in the custom antibody
market
The key factor propelling the custom antibody market growth
is the increasing demand for precision medicine and targeted therapeutics. With
the growing number of R&D activities and better understanding of the
molecular basis of complex diseases like cancer, autoimmune disorders, and
infectious diseases, researchers need highly specific antibodies to identify
and manipulate disease-related proteins. For instance, in June 2025, BioNTech
and Bristol Myers Squibb signed a global collaboration to co-develop
and co-commercialize BNT327, BioNTech’s PD‑L1 × VEGF‑A next-generation
bispecific antibody for multiple solid tumor types.
Custom antibodies have a specific ability to bind precisely
to unique epitopes, which can improve the detection in diagnostics and enhance
efficacy in therapeutic applications. Additionally, biotech and pharma
companies are investing more in custom antibody production to support the
development of ADCs (antibody-drug conjugates) and other advanced biologics.
For example, in December 2022, Merck announced an exclusive license and
collaboration agreement with Kelun-Biotech to co-develop seven investigational preclinical
antibody-drug conjugates (ADCs) for cancer treatment. This trend not only fuels
market demand but also expands the applications of custom antibodies.
Technological innovations and collaborations boost custom
antibody efficiency
In the evolving landscape of biotechnology, custom
antibodies have emerged as an invaluable tool, propelling technological
advancements in the diagnostic and therapeutic areas. One such notable
innovation is the use of custom antibodies in phage display technology. This
method allows scientists to rapidly screen billions of antibody variants and
identify those with optimal binding to a specific target antigen.
Unlike other methods, this method has gained widespread
adoption in industry and academic research, as it enhances the speed,
scalability, and ability to produce tailored antibodies, which are significant
for therapeutic applications. For instance,
- In
December 2024, Antibody Solutions received approval to become a CRO for
Levena’s Singularity™ SAPIEN™ Mouse platform, a transgenic animal model
which allows researchers to generate high-affinity, human-derived
antibodies more efficiently for both therapeutic and diagnostic
applications
- In
March 2024, Sino Biological, Inc. announced a collaboration with Rapid
Novor, Inc. Under this agreement, Sino Biological leveraged Rapid Novors'
REmAb monoclonal antibody (mAb) sequencing platform alongside its custom
antibody development and production services, providing a seamless
pipeline from antibody discovery to delivery
The increasing collaborations among biotech companies and
research organizations has improve antibody performance and making the
development process more efficient and reproducible. With the growing number of
technological innovations, the barrier to entry for high-quality custom
antibody production is being lowered, making it more accessible for a broader
range of users in the research and diagnostics field.
Competitive Landscape Analysis
The global custom antibody market is marked by the presence
of established and emerging market players such as Thermo Fisher
Scientific Inc.; Abcam plc; Bio-Rad Laboratories, Inc; Creative
Biolabs; Merck KGaA; Agilent Technologies Inc; GenScript; Laboratory
Corporation of America; Danaher Corporation; Kaneka Eurogentec S.A.;
Bio-Techne; and Sino Biological, Inc., among others. Some of the
key strategies adopted by market players include new product development,
strategic partnerships and collaborations, and geographic expansion.
Download a sample
report for in-depth competitive insights
https://meditechinsights.com/custom-antibody-market/request-sample/
Global Custom Antibody Market Segmentation
This report by Medi-Tech Insights provides the size of
the global custom antibody market at the regional- and country-level from
2023 to 2030. The report further segments the market based on type, service,
source, application, and end-user.
Market Size & Forecast (2023-2030), By Type, USD
Million
- Monoclonal
Antibodies
- Polyclonal
Antibodies
- Recombinant
Antibodies
- Others
Market Size & Forecast (2023-2030), By Service, USD
Million
- Antibody
Development
- Antibody
Production & Purification
- Antibody
Fragmentation & Labelling
Market Size & Forecast (2023-2030), By Source, USD
Million
- Mice
- Rabbit
- Others
Market Size & Forecast (2023-2030), By Application,
USD Million
- Oncology
- Infectious
Diseases
- Neurology
- Stem
cells
- Immunology
- Cardiovascular
Diseases
- Others
Market Size & Forecast (2023-2030), By End-user, USD
Million
- Hospitals
& Clinics
- Academic
& Research Institutes
- CRO
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment